First detection of Aspergillus fumigatus azole-resistant strain due to Cyp51A TR46/Y121F/T289A in an azole-naive patient in Spain

New Microbes and New Infections

Volumn 6, Issue , 2015, Pages 33-34

  Pelaez, T ^a,b   Monteiro, M C ^c   Garcia Rubio, R ^a,b   Bouza, E ^a,b   Gomez Lopez, A ^c   Mellado, E ^c  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Aspergillus fumigatus; Azole resistance spread; Cyp51A; Resistance mechanism

Indexed keywords

ITRACONAZOLE; PHENYLALANINE; POSACONAZOLE; VORICONAZOLE;

AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; BROTH DILUTION; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY FAILURE; DISEASE SURVEILLANCE; DYSPNEA; FEVER; FUNGAL STRAIN; FUNGUS ISOLATION; GENE SEQUENCE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THORAX PAIN;

ASPERGILLUS FUMIGATUS;

EID: 84930683806     PISSN: 20522975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmni.2015.04.005     Document Type: Article

References (10)

1. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008 Jun 15, 46(12):1813-1821. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.
2. Mellado E., Garcia-Effron G., Alcazar-Fuoli L., Melchers W.J., Verweij P.E., Cuenca-Estrella M., et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007 Jun, 51(6):1897-1904.
3. van der Linden J.W., Camps S.M., Kampinga G.A., Arends J.P., Debets-Ossenkopp Y.J., Haas P.J., et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013, 57:513-520.
4. Arendrup M.C., Cuenca-Estrella M., Lass-Flörl C., Hope W.W. European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect 2012, 18:E248-E250.
5. Verweij P.E., Howard S.J., Melchers W.J., Denning D.W. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009, 12:141-147.
6. van der Linden J.W., Snelders E., Kampinga G.A., Rijnders B.J., Mattsson E., Debets-Ossenkopp Y.J., et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 2011, 17:1846-1854.
7. Vermeulen E., Maertens J., Schoemans H., Lagrou K. Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. Euro Surveill 2012, 17(48).
8. Fischer J., van Koningsbruggen-Rietschel S., Rietschel E., Vehreschild M.J., Wisplinghoff H., Krönke M, et al. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients. J Antimicrob Chemother 2014 Jun, 69(6):1533-1536.
9. Astvad K.M., Jensen R.H., Hassan T.M., Mathiasen E.G., Thomsen G.M., Pedersen U.G., et al. First detection of TR46/Y121F/T289A and of TR34/L98H in azole naïve patients in Denmark despite negative findings in the environment. Antimicrob Agents Chemother 2014, 58:5096-5101.
10. Chowdhary A., Sharma C., Hagen F., Meis J.F. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol 2014, 9:697-711.